4.2. Psilocybin
4.2.1. Palliative care and cancer-related pain
In a randomized, double-blind, cross-over trial of very low
(placebo-like) dose (1 or 3 mg/70 kg) vs. high dose (22 or 30 mg/70 kg)
psilocybin that the substance is indeed able to increase well-being and
life satisfaction among patients with cancer.81Unfortunately, this study did not include pain as an outcome, but
mechanistic plausibility remains. Furthermore, psilocybin has been
explored in the context of end-of-life care, where it may alleviate
psychological distress associated with dying, enhance existential
well-being and improve the quality of life.81